Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AACR’s “Most Likely To Succeed” Anticancer Technologies

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The AACR report celebrates “paradigm-shifting technologies and research areas that could dramatically accelerate advances against all types of cancer.” Some of the advanced technologies that the association thinks are “likely to be successful” include:

You may also be interested in...

Celgene Expands Agios Collaboration In Cancer Metabolism

Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.

Eisai Deal Puts Epizyme In Position To Advance Lead Program

Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.

Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation

An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts